• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MiR-18a表达上调会降低Dicer的表达,并赋予三阴性乳腺癌对紫杉醇的抗性。

MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.

作者信息

Sha L-Y, Zhang Y, Wang W, Sui X, Liu S-K, Wang T, Zhang H

机构信息

Department of Pharmacy, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

出版信息

Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2201-8.

PMID:27338043
Abstract

OBJECTIVE

MiR-18a is a miRNA that is aberrantly overexpressed in triple-negative breast cancer (TNBC). However, its biophysical function in TNBC is still not clear. In this study, we investigated the association among miR-18a dysregulation, Dicer dysregulation and paclitaxel (PTX) resistance in TNBC cells.

PATIENTS AND METHODS

20 TNBC patients who received neoadjuvant chemotherapy before surgery were recruited. MiR-18a expression was quantified using QRT-PCR. The effects of miR-18a overexpression or knockdown on cell viability and apoptosis of PTX sensitive MDA-MB-231 cells and PTX resistant MDA-MB-231 cells after PTX treatment were studied. The influence of miR-18a overexpression on Dicer expression was measured by qRT-PCR and Western blot analysis.

RESULTS

Tissues from patients with stable disease (SD, n = 5) and progressive disease (PD, n = 2) to paclitaxel (PTX) containing neoadjuvant chemotherapy had significantly higher miR-18a expression than that from patients with partial response (PR, n = 13). MDA-MB-231/PTX cells had higher miR-18a expression than MDA-MB-231 cells. MiR-18a overexpression directly led to Dicer repression at mRNA and protein level. MiR-18a overexpression significantly increased PTX IC50 and reduced PTX induced cell apoptosis, while miR-18a suppression substantially decreased PTX IC50 and increased PTX induced cell apoptosis.

CONCLUSIONS

This study found that miR-18a is an important miRNA that suppresses Dicer expression and increases PTX resistance in TNBC cells.

摘要

目的

MiR-18a是一种在三阴性乳腺癌(TNBC)中异常高表达的微小RNA。然而,其在TNBC中的生物物理功能仍不清楚。在本研究中,我们调查了TNBC细胞中MiR-18a失调、Dicer失调与紫杉醇(PTX)耐药性之间的关联。

患者与方法

招募20例术前接受新辅助化疗的TNBC患者。使用QRT-PCR对MiR-18a表达进行定量。研究了MiR-18a过表达或敲低对PTX处理后PTX敏感的MDA-MB-231细胞和PTX耐药的MDA-MB-231细胞活力和凋亡的影响。通过qRT-PCR和蛋白质印迹分析测量MiR-18a过表达对Dicer表达的影响。

结果

对含紫杉醇(PTX)的新辅助化疗病情稳定(SD,n = 5)和病情进展(PD,n = 2)的患者组织中MiR-18a表达明显高于部分缓解(PR,n = 13)的患者。MDA-MB-231/PTX细胞中MiR-18a表达高于MDA-MB-231细胞。MiR-18a过表达直接导致Dicer在mRNA和蛋白质水平受到抑制。MiR-18a过表达显著增加PTX的半数抑制浓度(IC50)并减少PTX诱导的细胞凋亡,而抑制MiR-18a则大幅降低PTX的IC50并增加PTX诱导的细胞凋亡。

结论

本研究发现MiR-18a是一种重要的微小RNA,可抑制TNBC细胞中Dicer的表达并增加PTX耐药性。

相似文献

1
MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.MiR-18a表达上调会降低Dicer的表达,并赋予三阴性乳腺癌对紫杉醇的抗性。
Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2201-8.
2
MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway.MiR-18a上调通过抑制mTOR信号通路增强三阴性癌细胞的自噬。
Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2194-200.
3
LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy.长链非编码RNA PRKCQ-AS1通过miR-361-5p/PIK3C3介导的自噬调节三阴性乳腺癌细胞对紫杉醇的耐药性。
Clin Exp Pharmacol Physiol. 2023 Jun;50(6):431-442. doi: 10.1111/1440-1681.13758. Epub 2023 Mar 14.
4
Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.长链非编码 RNA CASC2 通过调节 miR-18a-5p/CDK19 促进乳腺癌对紫杉醇的耐药性。
Histochem Cell Biol. 2019 Oct;152(4):281-291. doi: 10.1007/s00418-019-01794-4. Epub 2019 Jul 27.
5
LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.LIN9 通过上调 CCSAP 赋予三阴性乳腺癌细胞紫杉醇耐药性。
Sci China Life Sci. 2020 Mar;63(3):419-428. doi: 10.1007/s11427-019-9581-8. Epub 2019 Aug 14.
6
MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.微小RNA-101通过抑制人三阴性乳腺癌中MCL-1的表达来抑制细胞进展并增加紫杉醇敏感性。
Oncotarget. 2015 Aug 21;6(24):20070-83. doi: 10.18632/oncotarget.4039.
7
circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.环状 RNA(circRNA)GFRA1 通过 miR-361-5p/TLR4 通路影响三阴性乳腺癌细胞对紫杉醇的敏感性。
J Biochem. 2021 Jul 3;169(5):601-611. doi: 10.1093/jb/mvaa148.
8
Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.紫杉醇耐药性三阴性乳腺癌中 p300 的上调:通过 PCK1/AMPK 轴对细胞增殖的影响。
Pharmacogenomics J. 2024 Feb 20;24(2):5. doi: 10.1038/s41397-024-00324-3.
9
MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.miRNA-5195-3p 通过下调 EIF4A2 增强三阴性乳腺癌对紫杉醇的化疗敏感性。
Cell Mol Biol Lett. 2019 Jul 1;24:47. doi: 10.1186/s11658-019-0168-7. eCollection 2019.
10
[Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].[miR-342-3p对三阴性乳腺癌化疗敏感性的影响]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 May;39(5):488-95. doi: 10.3969/j.issn.1672-7347.2014.05.009.

引用本文的文献

1
Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives.通过遗传、表观遗传和免疫调节机制解读乳腺癌治疗耐药性:从分子见解到转化前景
Cancer Drug Resist. 2025 Jul 21;8:36. doi: 10.20517/cdr.2025.69. eCollection 2025.
2
MicroRNA-driven organ-specific metastasis in triple-negative breast cancer: biogenesis, mechanisms, and therapeutic approaches.微小RNA驱动的三阴性乳腺癌器官特异性转移:生物发生、机制及治疗方法
Med Oncol. 2025 Jun 28;42(8):296. doi: 10.1007/s12032-025-02846-7.
3
Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer.
利用功能获得性筛选鉴定三阴性乳腺癌中参与紫杉醇耐药的微小RNA
Int J Mol Sci. 2024 Dec 20;25(24):13630. doi: 10.3390/ijms252413630.
4
Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial-Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative Breast Cancer.阐明 microRNA-18a 在推动 ER 阴性乳腺癌中混合上皮-间充质表型并驱动恶性进展中的作用。
Cells. 2024 May 10;13(10):821. doi: 10.3390/cells13100821.
5
Protective effect of miR-18a in resected liver metastases of colorectal cancer and FOLFOX treatment.miR-18a 对结直肠癌切除术后肝转移及 FOLFOX 治疗的保护作用。
Cancer Rep (Hoboken). 2023 Dec;6(12):e1899. doi: 10.1002/cnr2.1899. Epub 2023 Sep 12.
6
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy.乳腺癌:微小RNA监测化疗耐药性及全身治疗
Front Oncol. 2023 Jun 16;13:1155254. doi: 10.3389/fonc.2023.1155254. eCollection 2023.
7
Non-coding RNA's prevalence as biomarkers for prognostic, diagnostic, and clinical utility in breast cancer.非编码 RNA 作为乳腺癌预后、诊断和临床应用的生物标志物的普遍性。
Funct Integr Genomics. 2023 Jun 4;23(2):195. doi: 10.1007/s10142-023-01123-y.
8
Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy.自噬与乳腺癌:在生长、进展和治疗中相互关联。
Cells. 2023 Apr 14;12(8):1156. doi: 10.3390/cells12081156.
9
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.三阴性乳腺癌与新辅助化疗反应的预测标志物:一项系统综述。
Int J Mol Sci. 2023 Feb 3;24(3):2969. doi: 10.3390/ijms24032969.
10
miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.miRNAs 作为新辅助化疗治疗预测因子和预后生物标志物在乳腺癌中的系统评价和荟萃分析。
Breast Cancer Res Treat. 2022 Aug;194(3):483-505. doi: 10.1007/s10549-022-06642-z. Epub 2022 Jun 21.